{"id":"opt-80","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4111629","moleculeType":"Small molecule","molecularWeight":"416.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OPT-80 (fidaxomicin) is a non-systemic antibiotic that acts locally in the colon by binding to bacterial RNA polymerase, inhibiting transcription and protein synthesis in Gram-positive bacteria, particularly Clostridioides difficile. It has minimal systemic absorption and is designed to treat infections in the gastrointestinal tract while maintaining a favorable safety profile.","oneSentence":"OPT-80 is a macrocyclic antibiotic that inhibits bacterial protein synthesis by binding to the bacterial ribosome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:31.507Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile infection (CDI)"}]},"trialDetails":[{"nctId":"NCT02437591","phase":"PHASE4","title":"Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2015-08-13","conditions":"Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI)","enrollment":25},{"nctId":"NCT02179658","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-06-23","conditions":"Clostridium Difficile","enrollment":210},{"nctId":"NCT02254967","phase":"PHASE4","title":"A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-06","conditions":"Clostridium Difficile","enrollment":364},{"nctId":"NCT02692651","phase":"PHASE4","title":"A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-05-01","conditions":"Clostridium Difficile Infection (CDI)","enrollment":144},{"nctId":"NCT01591863","phase":"PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-06-15","conditions":"Clostridium Difficile-associated Diarrhea","enrollment":38},{"nctId":"NCT01691248","phase":"PHASE3","title":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-10-10","conditions":"Clostridium Difficile-Associated Diarrhea (CDAD)","enrollment":611},{"nctId":"NCT00468728","phase":"PHASE3","title":"PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-10-04","conditions":"Clostridium Infections, Diarrhea","enrollment":535},{"nctId":"NCT00314951","phase":"PHASE3","title":"Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-05-02","conditions":"Clostridium Infections, Diarrhea","enrollment":629},{"nctId":"NCT00097422","phase":"PHASE2","title":"OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2004-11-01","conditions":"Diarrhea","enrollment":""},{"nctId":"NCT01813448","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-02","conditions":"Pharmacokinetics of Fidaxomicin, Healthy Subjects","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["fidaxomicin"],"phase":"phase_3","status":"active","brandName":"OPT-80","genericName":"OPT-80","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPT-80 is a macrocyclic antibiotic that inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Clostridioides difficile infection (CDI).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}